Lb Pharmaceuticals (LBRX) Common Equity (2024 - 2026)

Lb Pharmaceuticals' Common Equity history runs 3 years deep, the most recent figure standing at $378.7 million for Q1 2026.

• On a quarterly basis, Common Equity rose 481.22% year-over-year to $378.7 million in Q1 2026; TTM through Mar 2026 was $378.7 million, a 481.22% increase from a year earlier, with the FY2025 full-year figure at $301.3 million, up 418.66% from the prior year.
• Common Equity climbed to $378.7 million in Q1 2026 per LBRX's latest filing, from $301.3 million in the prior quarter.
• Across five years, Common Equity topped out at $378.7 million in Q1 2026 and bottomed at -$99.3 million in Q1 2025.
• The 3-year median for Common Equity is $104.9 million (2024), against an average of $117.5 million.
• Across the five-year window, Common Equity jumped 418.66% in 2025 and surged 481.22% in 2026, its largest moves.
• Year by year, Common Equity stood at -$94.6 million in 2024, then soared by 418.66% to $301.3 million in 2025, then rose by 25.68% to $378.7 million in 2026.
• Per Business Quant, the three latest LBRX Common Equity figures stand at $378.7 million (Q1 2026), $301.3 million (Q4 2025), and $310.2 million (Q3 2025).